We are excited to announce our latest publication is now available online: “Prognostic value of 17-Gene genomic prostate score (GPS) in patients with clinically localized prostate cancer: a meta-analysis.”
https://pubmed.ncbi.nlm.nih.gov/38783246/
The meta-analysis evaluated the prognostic value of the GPS in patients with clinically localized prostate cancer. The meta-analysis included 1962 patients with NCCN very low-, low-, favorable intermediate-, unfavorable intermediate-, and high-risk prostate cancer with age ranging from 60 to 65 years and follow-up from 20 months to 15.5 years. The endpoints analyzed were biochemical recurrence/failure, distant metastasis, and prostate cancer-specific mortality. The meta-analysis demonstrated that GPS was significantly associated with biochemical recurrence/failure, distant metastasis, and prostate cancer-specific mortality as a continuous (per 20-unit increase) and dichotomous variable. These findings corroborate the GPS as a prognostic biomarker for predicting adverse outcomes in patients with clinically localized prostate cancer.
Key Takeaways
· The meta-analysis included 1962 patients with NCCN very low-, low-, FIR-, UFIR-, and high risk.
· Prostate cancer patients with higher GPS had a higher likelihood of BCR, DM, and PCSM, regardless of the NCCN risk group.
· GPS was significantly associated with BCR/BCF, DM, and PCSM as a continuous (per 20-unit increase) and dichotomous variable (>40 vs. ≤40).